Scharl S, et al. - Researchers designed this retrospective study to ascertain the influence of post-operative radio-, chemo, and radiochemotherapy on survival time and recurrence rates among high-grade endometrial cancer patients. Findings suggested that treating high-grade endometrial cancer with post-operative radiochemotherapy (RCT) had a survival benefit.

Methods

• Researchers retrospectively analyzed 284 high-grade endometrial cancer patients (FIGOI–III, or unknown classification) diagnosed between 1998 and 2015.
• Surgery was performed on all patients.
• For post-operative treatment modalities of radiotherapy alone (RT), chemotherapy alone (CTX), RCT, and observation (OBS), they compared overall survival (OS), recurrence-free survival (RFS), and recurrence rates.

Results

• Significantly improved 5-year OS of 94.1% (HR 0.104, CI 0.013-0.809) and 62.1% (HR 0.615, CI 0.390-0.969) were evident with post-operative RCT and RT, respectively, compared to 43.6% for OBS.
• CTX resulted in no significant improvement in OS leading to a 5-year OS of 56.5% (HR 0.783, CI 0.224–2.740).
• For patients treated with RCT, 5-year recurrence rate was lowest (5.3%).
• The RCT group showed 5-year RFS of 94.1%, which was significantly superior to 58.8% for RT (HR 9.034, CI 1.184–68.948), 56% for CTX (HR 12.738, CI 1.337–121.346), and 37.4% for OBS (HR 16.407, CI 2.127–126.575), respectively.
• Researchers noticed that in comparison with OBS, RT alone resulted in a significant improvement in RFS (HR 0.551, CI 0.354–0.856).